Current and historical daily PE Ratio for Shandong Xinhua Pharmaceutical Co Ltd (
) from 1996 to May 16 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Shandong Xinhua Pharmaceutical stock (HKSE:00719) PE ratio as of May 16 2024 is 7.67.
More Details
Shandong Xinhua Pharmaceutical Co Ltd (HKSE:00719) PE Ratio (TTM) Chart
Shandong Xinhua Pharmaceutical Co Ltd (HKSE:00719) PE Ratio (TTM) Historical Data
View and export this data going back to 1996. Start your Free Trial
Total 1208
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Shandong Xinhua Pharmaceutical PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-17 | 7.7 | 2024-03-08 | 7.0 |
| 2024-05-16 | 7.7 | 2024-03-07 | 7.0 |
| 2024-05-14 | 7.7 | 2024-03-06 | 7.0 |
| 2024-05-13 | 7.7 | 2024-03-05 | 7.0 |
| 2024-05-10 | 7.5 | 2024-03-04 | 7.0 |
| 2024-05-09 | 7.3 | 2024-03-01 | 7.0 |
| 2024-05-08 | 7.3 | 2024-02-29 | 7.0 |
| 2024-05-07 | 7.2 | 2024-02-28 | 6.8 |
| 2024-05-06 | 7.2 | 2024-02-27 | 7.0 |
| 2024-05-03 | 7.1 | 2024-02-26 | 7.0 |
| 2024-05-02 | 7.2 | 2024-02-23 | 7.0 |
| 2024-04-30 | 7.1 | 2024-02-22 | 6.9 |
| 2024-04-29 | 7.2 | 2024-02-21 | 6.9 |
| 2024-04-26 | 7.1 | 2024-02-20 | 6.8 |
| 2024-04-25 | 7.0 | 2024-02-19 | 6.8 |
| 2024-04-24 | 6.9 | 2024-02-16 | 7.0 |
| 2024-04-23 | 6.9 | 2024-02-15 | 6.8 |
| 2024-04-22 | 6.8 | 2024-02-14 | 6.7 |
| 2024-04-19 | 6.8 | 2024-02-09 | 6.8 |
| 2024-04-18 | 6.9 | 2024-02-08 | 6.8 |
| 2024-04-17 | 6.9 | 2024-02-07 | 6.6 |
| 2024-04-16 | 6.8 | 2024-02-06 | 6.5 |
| 2024-04-15 | 7.0 | 2024-02-05 | 6.2 |
| 2024-04-12 | 7.0 | 2024-02-02 | 6.3 |
| 2024-04-11 | 7.0 | 2024-02-01 | 6.4 |
| 2024-04-10 | 7.0 | 2024-01-31 | 6.3 |
| 2024-04-09 | 7.0 | 2024-01-30 | 6.6 |
| 2024-04-08 | 6.8 | 2024-01-29 | 6.7 |
| 2024-04-05 | 6.8 | 2024-01-26 | 6.7 |
| 2024-04-03 | 6.9 | 2024-01-25 | 6.9 |
| 2024-04-02 | 7.0 | 2024-01-24 | 6.8 |
| 2024-03-28 | 7.0 | 2024-01-23 | 6.5 |
| 2024-03-27 | 6.7 | 2024-01-22 | 6.5 |
| 2024-03-26 | 6.7 | 2024-01-19 | 6.5 |
| 2024-03-25 | 6.7 | 2024-01-18 | 6.7 |
| 2024-03-22 | 6.8 | 2024-01-17 | 6.7 |
| 2024-03-21 | 7.0 | 2024-01-16 | 7.1 |
| 2024-03-20 | 7.0 | 2024-01-15 | 7.2 |
| 2024-03-19 | 7.0 | 2024-01-12 | 7.1 |
| 2024-03-18 | 7.1 | 2024-01-11 | 7.1 |
| 2024-03-15 | 7.0 | 2024-01-10 | 7.0 |
| 2024-03-14 | 7.1 | 2024-01-09 | 7.0 |
| 2024-03-13 | 7.1 | 2024-01-08 | 7.0 |
| 2024-03-12 | 7.1 | 2024-01-05 | 7.1 |
| 2024-03-11 | 7.0 | 2024-01-04 | 7.2 |
Shandong Xinhua Pharmaceutical Co Ltd (HKSE:00719) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Shandong Xinhua Pharmaceutical Co Ltd
NAICS : 325414
SIC : 2834
ISIN : CNE100000411
Share Class Description:
HKSE:00719: Class HCompare
Compare
Traded in other countries / regions
000756.China00719.Hong KongXIN.GermanySHNXY.USA IPO Date
1996-12-31Description
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates the business through the following segments: Chemical bulk drugs which also generates key revenue, Preparations, Chemical intermediates, and other products. The company provides chemical bulk drug products, including metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, and L-dopa, it also dispenses formulation products such as compound liquorice tablets and nimodipine tablets. Its products address disorders related to the central nervous system and the cerebrovascular system with the help of antipyretics and analgesics. Geographically, the company generates a majority of its revenue from China (including Hong Kong), America, Europe and others.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers